Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
The chart shows the growth of an initial investment of $10,000 in Penumbra, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Penumbra, Inc. (PEN) has returned 6.32% so far this year and 31.10% over the past 12 months. Looking at the last ten years, PEN has achieved an annualized return of 21.61%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Penumbra, Inc. (PEN) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 15.27% | -4.01% | -4.07% | 0.14% | ||||||||
| 2025 | 11.78% | 7.75% | -6.33% | 9.61% | -9.04% | -3.75% | -1.00% | 9.17% | -6.93% | -10.46% | 29.95% | 5.17% |
| 2024 | 1.82% | -7.15% | -4.92% | -11.97% | -3.67% | -5.47% | -7.17% | 19.91% | -4.29% | 18.02% | 5.64% | -2.28% |
| 2023 | 10.25% | 3.36% | 7.40% | 2.80% | 8.12% | 11.64% | -11.16% | -11.84% | -9.27% | -20.68% | 16.33% | 13.34% |
| 2022 | -20.79% | -2.89% | 1.05% | -22.17% | -14.72% | -15.76% | 12.05% | 19.73% | 16.91% | -10.32% | 19.84% | 6.52% |
| 2021 | 49.78% | 2.61% | -6.08% | 12.24% | -18.68% | 9.42% | -2.60% | 2.51% | -3.00% | 3.55% | -11.66% | 15.60% |
| 2020 | 6.88% | -5.83% | -3.88% | 13.48% | -1.21% | 3.47% | 23.92% | -6.33% | -7.08% | 33.14% | -15.65% | -21.55% |
| 2019 | 20.67% | -7.87% | 9.13% | -9.38% | 5.80% | 12.12% | 4.10% | -13.66% | -7.13% | 15.59% | 12.72% | -7.14% |
| 2018 | 7.21% | 9.29% | 7.08% | 8.32% | 27.80% | -14.88% | 3.08% | -2.39% | 7.89% | -9.30% | 1.61% | -12.24% |
| 2017 | 12.15% | 7.41% | 9.51% | 2.70% | -3.04% | 5.53% | -7.22% | 5.52% | 5.00% | 11.47% | 5.56% | -10.89% |
| 2016 | 18.68% | -3.51% | 12.84% | 14.81% | 2.57% | 8.17% | -12.60% | -6.07% | 2.82% |
The charts below present risk-adjusted performance metrics for Penumbra, Inc. (PEN) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of PEN compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Penumbra, Inc. volatility is 0.57%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.83B | 1.53B | 1.56B | 1.37B | 1.24B | 822.98M | 665.90M | 515.01M | 476.67M | 308.25M | 263.85M |
| Temporary Equity Attributable To Parent (USD) | - | - | - | - | - | - | - | - | - | - | - |
| Temporary Equity (USD) | - | - | - | - | - | - | - | - | - | - | - |
| Equity Attributable To Parent (USD) | 1.43B | 1.15B | 1.18B | 998.86M | 953.93M | 641.50M | 485.89M | 422.24M | 400.41M | 266.55M | 232.52M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | -3.71M | -279.00K | 175.00K | - | - | - |
| Equity (USD) | 1.43B | 1.15B | 1.18B | 998.86M | 953.93M | 637.79M | 485.61M | 422.42M | 400.41M | 266.55M | 232.52M |
| Noncurrent Liabilities (USD) | 215.78M | 223.91M | 226.22M | 227.10M | 167.13M | 79.26M | 89.24M | 26.53M | 24.68M | 5.91M | 3.18M |
| Other Current Liabilities (USD) | 63.00M | 52.82M | 58.59M | 57.77M | 49.76M | 41.74M | 38.21M | 24.05M | 22.82M | 14.73M | 11.93M |
| Wages (USD) | 85.40M | 74.20M | 65.40M | 60.48M | 60.02M | 50.08M | 37.73M | 33.84M | 22.00M | 16.96M | 13.65M |
| Accounts Payable (USD) | 34.74M | 31.33M | 27.16M | 26.68M | 13.42M | 14.11M | 15.11M | 8.18M | 6.76M | 4.11M | 2.57M |
| Current Liabilities (USD) | 183.13M | 158.35M | 151.14M | 144.93M | 123.20M | 105.93M | 91.05M | 66.06M | 51.58M | 35.80M | 28.15M |
| Liabilities (USD) | 398.92M | 382.25M | 377.36M | 372.03M | 290.32M | 185.20M | 180.29M | 92.59M | 76.26M | 41.71M | 31.33M |
| Other Non-current Assets (USD) | 486.21M | 512.90M | 497.16M | 469.01M | 413.30M | 146.47M | 125.55M | 41.63M | 39.76M | 22.96M | 10.54M |
| Intangible Assets (USD) | 6.19M | 6.51M | 71.06M | 81.16M | 90.62M | 10.64M | 25.41M | 27.25M | 23.78M | - | - |
| Fixed Assets (USD) | 117.44M | 62.64M | 72.69M | 65.02M | 58.86M | 48.17M | 51.81M | 35.41M | 30.90M | 21.46M | 8.95M |
| Noncurrent Assets (USD) | 609.84M | 582.06M | 640.90M | 615.19M | 562.78M | 205.28M | 202.77M | 104.28M | 94.43M | 44.43M | 19.49M |
| Other Current Assets (USD) | 785.14M | 544.39M | 527.38M | 421.69M | 417.97M | 398.18M | 310.14M | 294.99M | 283.22M | 186.24M | 180.16M |
| Prepaid Expenses (USD) | - | - | - | - | - | - | - | - | 4.11M | 4.57M | 7.44M |
| Inventory (USD) | 431.55M | 406.74M | 388.02M | 334.01M | 263.50M | 219.53M | 152.99M | 115.74M | 94.90M | 73.01M | 56.76M |
| Current Assets (USD) | 1.22B | 951.13M | 915.40M | 755.70M | 681.47M | 617.70M | 463.13M | 410.73M | 382.23M | 263.83M | 244.36M |
| Assets (USD) | 1.83B | 1.53B | 1.56B | 1.37B | 1.24B | 822.98M | 665.90M | 515.01M | 476.67M | 308.25M | 263.85M |
Boston Scientific is well-positioned to capitalize on global aging demographics, with products addressing age-related conditions like atrial fibrillation, chronic pain, and Parkinson's disease. Recent acquisitions of Penumbra and Silk Road Medical expand its stroke treatment capabilities. Despite strong fundamentals and double-digit growth, the stock has been beaten down following conservative 2026 guidance, creating a potentially attractive valuation opportunity.
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.
Monteverde & Associates PC, a class action law firm, is investigating four merger transactions: Penumbra's sale to Boston Scientific, RAPT Therapeutics' sale to GSK, Nathan's Famous' sale to Smithfield Foods, and Lisata Therapeutics' sale to Smithfield Foods. The firm is seeking shareholders who may have concerns about these deals.
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.
Boston Scientific has issued a recall of certain AXIOS stents and electrocautery-enhanced delivery systems due to deployment and expansion difficulties. As of December 23, the company reported 167 serious injuries and 3 deaths associated with the issue. The FDA is actively reviewing the potentially high-risk device issue. The complications occur during delivery, not after implantation.
Investor rights law firm Halper Sadeh LLC is investigating three companies for potential securities law violations and fiduciary duty breaches related to major transactions: Penumbra's $374 per share sale to Boston Scientific, Calavo's acquisition by Mission Produce for $14.85 cash plus stock, and Mission Produce's merger with Calavo. The firm is seeking increased consideration for shareholders and additional disclosures.
This week's M&A activity spans major acquisitions and bankruptcies. Boston Scientific agreed to acquire Penumbra for $14.6 billion, expanding its neurovascular presence. Devon Energy and Coterra Energy are in merger discussions to create a major shale producer. Paramount Skydance's lawsuit against Warner Bros. Discovery was rejected by a Delaware judge. BitMine Immersion invested $200 million in MrBeast's Beast Industries. Meanwhile, spirits producers Stoli Group USA and Kentucky Owl converted their Chapter 11 bankruptcies to Chapter 7 liquidation, and Sailormen Inc., a Popeyes franchisee, filed for bankruptcy.
The global neurovascular devices market is projected to grow from USD 3.6 billion in 2024 to USD 6.8 billion by 2032, driven by increasing prevalence of neurovascular disorders, technological advancements, and growing preference for minimally invasive procedures. North America leads the market with 30% share, while Asia-Pacific emerges as a major growth driver. Key players include Johnson & Johnson, Medtronic, Stryker, and Terumo Corporation.
Boston Scientific agreed to acquire thrombectomy specialist Penumbra for $14.5 billion ($374 per share) in a cash-and-stock deal. Penumbra shareholders will receive approximately 73% cash and 27% equity. The acquisition allows Boston Scientific to enter fast-growing vascular segments. Penumbra reported strong preliminary Q4 2025 results with 21-24% revenue growth. Boston Scientific expects 6-8 cents per share dilution in year one, trending toward neutral to accretive thereafter. The deal is expected to close in 2026.
Markets traded cautiously on Tuesday despite benign inflation data (CPI at 2.7% YoY, core CPI at 2.6%) that supported Fed rate cut expectations. Silver surged 4.5% to $89/oz amid supply concerns. Major indices remained flat with the S&P 500 near record highs. Earnings results were mixed: JPMorgan fell 3% on weak investment banking fees, Delta slid 4% on soft guidance, while Moderna rallied 14% on bullish forecasts. Intel and AMD gained on analyst upgrades. Energy stocks outperformed as crude rose 2.7% to $61/barrel.
